MeiraGTx Holdings (MeiraGTx Holdings) EBIT : $-60.67 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is MeiraGTx Holdings EBIT?

MeiraGTx Holdings's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-17.19 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-60.67 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. MeiraGTx Holdings's annualized ROC % for the quarter that ended in Mar. 2024 was -104.37%. MeiraGTx Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -44.92%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. MeiraGTx Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -18.64%.

MeiraGTx Holdings EBIT Historical Data

The historical data trend for MeiraGTx Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MeiraGTx Holdings EBIT Chart

MeiraGTx Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-54.70

-57.85

-79.27

-124.67

-70.78

MeiraGTx Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-27.30	-26.23	-40.92	23.66	-17.19

Competitive Comparison of MeiraGTx Holdings's EBIT

For the Biotechnology subindustry, MeiraGTx Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MeiraGTx Holdings's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MeiraGTx Holdings's EV-to-EBIT falls into.

MeiraGTx Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.67 Mil.

MeiraGTx Holdings (NAS:MGTX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

MeiraGTx Holdings's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-187.088 * ( 1 - 0% )	/	( (187.648	+	170.863)	/ 2 )
=	-187.088	/	179.2555
=	-104.37 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	326.744	-	46.552	-	( 129.566	-	max(0, 67.078	-	159.622	+	129.566	))
=	187.648

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	309.235	-	36.615	-	( 119.206	-	max(0, 47.543	-	149.3	+	119.206	))
=	170.863

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

MeiraGTx Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-68.768	/	( ( (156.238 + max(-46.106, 0))	+	(149.934 + max(-26.432, 0)) )	/	2 )
=	-68.768	/	( ( 156.238	+	149.934 )	/	2 )
=	-68.768	/	153.086
=	-44.92 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(10.138	+	0	+	6.641)	-	(46.552	+	2.926	+	13.407)
=	-46.106

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(10.915	+	0	+	6.008)	-	(36.615	+	3.772	+	2.968)
=	-26.432

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

MeiraGTx Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-60.67	/	325.428
	=	-18.64 %

MeiraGTx Holdings EBIT Related Terms

Thank you for viewing the detailed overview of MeiraGTx Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

MeiraGTx Holdings (MeiraGTx Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MeiraGTx Holdings PLC (NAS:MGTX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

328:Germany

Address

450 East 29th Street, 14th Floor, New York, NY, USA, 10016

Website

https://www.meiragtx.com

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

Executives

Perceptive Life Sciences Master Fund Ltd	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Johnson & Johnson Innovation - Jjdc, Inc.	10 percent owner	410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Johnson & Johnson	10 percent owner	ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
Robert K Zeldin	officer: Chief Medical Officer	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Robert J Wollin	officer: General Counsel and Secretary	450 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Debra Yu	director	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Alexandria Forbes	director, officer: President & CEO	C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Richard Giroux	officer: Chief Operating Officer	C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Stuart Naylor	director, officer: Chief Dev. Officer	C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Joel S Marcus	director	C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Thomas E Shenk	director	C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Nicole Seligman	director	C/O VIACOM INC., 1515 BROADWAY, NEW YORK NY 10036
Perceptive Advisors Llc	director, 10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Ellen Hukkelhoven	director	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003